Compare Ascendis Pharma A/S (ASND) vs Sibanye Stillwater Ltd (SBSW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Sibanye Stillwater Ltd — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Sibanye Stillwater Ltd trades at $8.56 (market cap $5.95B). The key difference: Ascendis Pharma A/S is far larger — about 3× Sibanye Stillwater Ltd's market cap, and Sibanye Stillwater Ltd pays a 3.64% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | SBSW | |
|---|---|---|
Market Cap | $17.74B | $5.95B |
Sector | Health | Basic Materials |
52-Week High | $277.18 | $21.12 |
52-Week Low | $163.32 | $7.27 |
Enterprise Value | $18.11B | $7.57B |
Dividend Yield | — | 3.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Sibanye Stillwater (SBSW) trades at $8.55, down 0.12% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $7.30 billion in 2024, though revenue stabilized at $112.13 billion. Recent news highlights a potential turnaround with EBITDA growth and debt reduction plans, while analyst consensus is mixed with 42.9% buy ratings.
The outlook hinges on operational improvements and commodity price recovery. Key risks include persistent negative margins and high debt levels, but low valuation multiples may attract value investors if the company executes its turnaround strategy effectively.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Sibanye Stillwater Ltd
Sibanye Stillwater Ltd is a South Africa-focused mining company. The Group currently owns and operates five underground and surface gold operations in South Africa: the Cooke, DRDGOLD, Driefontein, and Kloof operations in the West Witwatersrand region, and the Beatrix Operation in the southern Free State province. In addition to mining, the company owns and manages extraction and processing facilities at its operations, where gold-bearing ore is treated and beneficiated to produce gold dore. The gold dore is further refined at Rand Refinery into gold bars with a purity of at least 99.5% and is then sold on international markets. Sibanye holds a 44% interest in Rand Refinery, global refiners of gold, and the largest in Africa. Rand Refinery markets gold to customers around the world.
Read more on SBSW →
